CDKN2A and lymphoma: Taken together, the monoclonal anti-p14 antibodies and adoptive T-cell transfer studies (passive immunization) demonstrate in vivo efficacy against aggressive mouse tumors (mammary carcinoma and lymphoma) that contain MMTV and express p14 on their surface [85].